2,867 Shares in The Clorox Company (NYSE:CLX) Bought by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. purchased a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 2,867 shares of the company's stock, valued at approximately $400,000.

Other hedge funds also recently added to or reduced their stakes in the company. Brown Miller Wealth Management LLC bought a new position in Clorox during the 1st quarter valued at about $399,000. Wedge Capital Management L L P NC grew its holdings in Clorox by 33.5% during the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company's stock valued at $4,198,000 after purchasing an additional 7,159 shares during the last quarter. California Public Employees Retirement System grew its holdings in Clorox by 1.3% during the 4th quarter. California Public Employees Retirement System now owns 565,810 shares of the company's stock valued at $91,893,000 after purchasing an additional 6,987 shares during the last quarter. Willis Investment Counsel grew its stake in Clorox by 9.1% in the 1st quarter. Willis Investment Counsel now owns 202,678 shares of the company's stock worth $29,844,000 after acquiring an additional 16,893 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV bought a new position in Clorox in the 1st quarter worth about $2,901,000. 78.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CLX shares. JPMorgan Chase & Co. decreased their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Barclays decreased their target price on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. UBS Group dropped their price target on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Evercore ISI set a $140.00 price target on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Finally, Morgan Stanley decreased their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $151.23.

Insider Activity at Clorox

In related news, Director Pierre R. Breber purchased 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.57% of the stock is currently owned by corporate insiders.

Clorox Stock Down 0.1%

NYSE:CLX traded down $0.12 during midday trading on Friday, reaching $120.81. 4,705,254 shares of the stock traded hands, compared to its average volume of 1,362,826. The Clorox Company has a 12-month low of $120.33 and a 12-month high of $171.37. The business has a 50-day moving average of $133.11 and a two-hundred day moving average of $146.77. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The stock has a market capitalization of $14.89 billion, a PE ratio of 21.69, a price-to-earnings-growth ratio of 2.73 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The firm had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same period in the previous year, the company earned $1.71 EPS. The company's revenue was down 8.0% on a year-over-year basis. On average, equities analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.